widespread use of DF was firmly established thanks to the exceptional devotion of our Italian colleagues. In the following, I shall focus on the impact of iron chelating treatment on survival in Thalassemia; examine the mechanism whereby DF protects the heart from iron toxicity, and: examine the potential usefulness of iron chelators in conditions unrelated to iron overload.
(I) Management of transfusional iron overload: Survival in thalassemic patients in recent years is definitely better than in the pre-DF era. The most extensive and detailed information on survival in thalassemia comes from Italy, where over 5000 patients with thalassemia major are treated and monitored by a remarkably well coordinated national study group of the National Association for Pediatric Oncology and Hematology (AIEOP). In Italy continuous subcutaneous DF treatment has been introduced and used systematically since 1978 (2) . In a report by Borgna-Pignatti et al (3) on 942 thalassemic patients from Italy, a steady improvement in survival has been shown for cohorts born in 1960-1964, 1965-1969 and 1970-1974 (4) . A unique feature of this model is the ability to correlate functional abnormalities in heart cell contractility and rhythmicity induced by iron toxicity, with structural aberrations such as alterations in membrane lipid and protein composition. Our studies in cultured heart cells have shown that 24-hour incubation with iron at concentrations ranging from 20 to 80 micrograms per ml resulted in a drastic decrease in the amplitude and rate of contractions, a dose-related decrease in the magnitude of the calcium-dependent overshoot potential, and gross abnormalities in rhythmicity resembling ventricular fibrillation in 20 to 30 % of culture plates (5) . All of these abnormalities were abolished by subsequent treatment with DF at a concentration of 0.3 mM. Volume 1, Nos. [2] [3] 1994 
